Incyte up 3% in Pre-Bell as Phase 3 Trial Meets Primary EndpointBy Ryan WallaceMarch 7, 2014 Incyte (INCY) is higher this morning after it disclosed that a pivotal Phase III trial of ruxolitinib compared to best…